

licensing in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Technology description follows.

### **Lentiviral Protein Delivery System for RNA-Guided Genome Editing**

**Description of Technology:** This invention provides an HIV-1-based lentiviral vector system for gene correction strategies involving a homologous recombination with a variation of the CRISPR/Cas9 system. Such systems are being explored as potential therapies for certain hereditary diseases. This system comprises (a) a lentivirus vector particle comprising a lentiviral genome which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, (b) a Cas9 protein, and optionally (c) a donor nucleic acid molecule comprising a second DNA sequence. In addition, the invention provides a host cell comprising the foregoing system, as well as a method of altering a DNA sequence in a host cell comprising contacting a host cell with the foregoing system. Alternatively, the invention also provides a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein, wherein the fusion protein binds to the lentivirus vector particle, as well as a lentiviral vector particle comprising such a fusion protein. Other such lentivirus-based vectors encode a guide RNA, which contains a specific sequence that recognizes a target gene, and a Cas9 endonuclease, which cuts at the specific site. However, such systems present some problems due to constitutive expression of Cas9 endonuclease in lentiviral vector-transduced cells and the large size of the Cas9 gene. The variation of this invention delivers the Cas9 endonuclease directly, instead of the gene encoding the protein.

**Potential Commercial Applications:** Clinical trials for hereditary diseases such as sickle-cell disease and beta-thalassemia are good market opportunities. Gene correction using the disclosed lentiviral vector system are being tested with respect to the beta-globin gene and the BCL11A gene to treat sickle-cell disease and will be used for induced pluripotent stem cell (iPS) generation.

**Development Stage:** Early-stage. In vitro data in cell-line models available.

**Inventors:** Naoya Uchida, Juan J. Haro Mora and John F. Tisdale (NHLBI).

**Intellectual Property:** US Application No. 62/236,223, filed October 2, 2015 and PCT/US2016/054759, filed

September 30, 2016, (NIH Reference No. E-165-2015/0.1).

**Publications:** Lentiviral protein delivery system for RNA-guided genome editing, PCT Publication No. WO/2017/059241, published April 6, 2017.

**Licensing Contact:** Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-435-4507; [thalhamc@mail.nih.gov](mailto:thalhamc@mail.nih.gov).

**Collaborative Research Opportunity:** The National Heart, Lung and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Denise Crooks at [crooksd@mail.nih.gov](mailto:crooksd@mail.nih.gov).

Dated: March 22, 2018.

**Cristina Thalhammer-Reyero**, Senior Licensing and Patenting Manager, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute.

[FR Doc. 2018-06364 Filed 3-28-18; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NICHD.

The meeting will be open to the public as indicated below, with the attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the Eunice Kennedy Shriver National Institute Of Child Health And Human Development, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Board of Scientific Counselors, NICHD.

**Date:** June 1, 2018.

**Open:** 8:00 a.m. to 11:45 a.m.

**Agenda:** A report by the Scientific Director, NICHD, on the status of the NICHD Division of Intramural Research; talks by various intramural scientists, and current organizational structure.

**Place:** National Institutes of Health, Building 31A, Conference Room 2A48, 31 Center Drive, Bethesda, MD 20892.

**Closed:** 11:45 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** National Institutes of Health, Building 31A, Conference Room 2A48, 31 Center Drive, Bethesda, MD 20892.

**Contact Person:** Constantine A. Stratakis, MD, D(med)Sci, Scientific Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Building 31A, Room 2A46, 31 Center Drive, Bethesda, MD 20892, 301-594-5984, [stratak@mail.nih.gov](mailto:stratak@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <https://www.nichd.nih.gov/about/meetings/Pages/index.aspx>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos.93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: March 23, 2018.

**Michelle Trout**,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-06259 Filed 3-28-18; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Board on Medical Rehabilitation Research. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

**Name of Committee:** National Advisory Board on Medical Rehabilitation Research.

Date: May 7–8, 2018.

Time: May 7, 2018, 9:00 a.m. to 5:00 p.m.

Agenda: NICHD Director's report;

Inclusion at NIH; Clinical Trials Policy Updates; Update on NIH Rehabilitation Research Plan Analysis; Communication and Dissemination Strategies; Pathways to Prevention.

Place: NICHD Offices, 6710B Rockledge Drive, Rooms 1425/1427, Bethesda, MD 20892.

Time: May 8, 2018, 8:30 a.m. to 12:00 p.m.

Agenda: Pragmatic Trials at NIH;

Rehabilitation 2030: WHO Effort; Scientific Presentation on Multimodal Approaches.

Place: NICHD Offices, 6710B Rockledge Drive, Rooms 1425/1427, Bethesda, MD 20892.

Contact Person: Ralph M. Nitkin, Ph.D., Deputy Director, National Center for Medical Rehabilitation Research (NCMRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Room 2116, MSC 7002, Bethesda, MD 20892, (301) 402–4206, [RN21e@nih.gov](mailto:RN21e@nih.gov).

Information is also available on the Institute's/Center's home page: <http://www.nichd.nih.gov/about/advisory/nabmrr/Pages/index.aspx> where the current roster and minutes from past meetings are posted. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: March 23, 2018.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–06258 Filed 3–28–18; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG–2018–0042]

### Chemical Transportation Advisory Committee; Vacancies

**AGENCY:** U.S. Coast Guard, Department of Homeland Security.

**ACTION:** Request for applications.

**SUMMARY:** The U.S. Coast Guard seeks applications for membership on the Chemical Transportation Advisory Committee. The Chemical Transportation Advisory Committee provides advice and makes recommendations on matters relating to the safe and secure marine transportation of hazardous materials insofar as they relate to matters within the United States Coast Guard's jurisdiction.

**DATES:** Completed applications should reach the U.S. Coast Guard on or before May 29, 2018.

**ADDRESSES:** Applicants should send a cover letter expressing interest in an appointment to the Chemical Transportation Advisory Committee that also identifies which membership category the applicant is applying under, along with a resume detailing the applicant's experience via one of the following methods:

• *By Email:* [jake.r.lobb2@uscg.mil](mailto:jake.r.lobb2@uscg.mil);

Subject Line: Chemical Transportation Advisory Committee;

• *By Fax:* (202) 372–8380 ATTN:

Lieutenant Jake Lobb; or

• *By Mail:* Lieutenant Jake Lobb, Alternate Designated Federal Official of the Chemical Transportation Advisory Committee, Commandant, Hazardous Materials Division (CG–ENG–5), U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, Stop 7509, Washington, DC 20593–7509.

### FOR FURTHER INFORMATION CONTACT:

Lieutenant Jake Lobb of the Chemical Transportation Advisory Committee; (202) 372–1428; [jake.r.lobb2@uscg.mil](mailto:jake.r.lobb2@uscg.mil).

**SUPPLEMENTARY INFORMATION:** The Chemical Transportation Advisory Committee is a federal advisory committee which operates under the provisions of the Federal Advisory Committee Act, 5 U.S.C. Appendix.

The Chemical Transportation Advisory Committee provides advice and recommendations to the Department of Homeland Security on matters relating to the safe and secure marine transportation of hazardous materials insofar as they relate to matters within the United States Coast Guard's jurisdiction.

The Chemical Transportation Advisory Committee meets at least twice per year. It may also meet for extraordinary purposes. Its subcommittees may meet to consider specific problems as required.

The U.S. Coast Guard will consider applications for 8 positions that become vacant on September 16, 2018. The membership categories are: Chemical manufacturing, marine handling or transportation of chemicals, vessel design and construction, marine safety or security, and marine environmental protection. All members of the Chemical Transportation Advisory Committee are Representatives. Each Chemical Transportation Advisory Committee member serves for a term of three years, and may serve no more than two consecutive three-year terms. A member appointed to fill an unexpired term may serve the remainder of that term. All members serve at their own expense and

receive no salary, reimbursement of travel expenses, or other compensation from the Federal Government.

The Department of Homeland Security does not discriminate in selection of Committee members on the basis of race, color, religion, sex, national origin, political affiliation, sexual orientation, gender identity, marital status, disabilities and genetic information, age, membership in an employee organization, or any other non-merit factor. The Department of Homeland Security strives to achieve a widely diverse candidate pool for all of its recruitment actions.

If you are interested in applying to become a member of the Committee, send your cover letter and resume to Lieutenant Jake Lobb, Alternate Designated Federal Official of the Chemical Transportation Advisory Committee, via one of the transmittal methods in the **ADDRESSES** section by the deadline in the **DATES** section of this notice. All email submittals will receive email receipt confirmation.

Dated: March 23, 2018.

Jeffrey G. Lantz,

Director, Commercial Regulations and Standards.

[FR Doc. 2018–06385 Filed 3–28–18; 8:45 am]

BILLING CODE 9110–04–P

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

[Docket ID: FEMA–2018–0012; OMB No. 1660–NEW]

### Agency Information Collection Activities: Proposed Collection; Comment Request; National Catastrophic Resource Catalog

**AGENCY:** U.S. Fire Administration, Federal Emergency Management Agency, DHS.

**ACTION:** Notice and request for comments.

**SUMMARY:** The Federal Emergency Management Agency (FEMA), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public to take this opportunity to comment on a new information collection. In accordance with the Paperwork Reduction Act of 1995, this notice seeks comments concerning the identification and cataloging of fire and emergency services personnel and equipment that might be available to support a catastrophic national disaster response.